Grade 5 adverse events
| . | Placebo + HDAC (N = 86) . | Laromustine + HDAC (N = 177) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Adverse events with death | 11 | 13% | 71 | 40% |
| Infectious deaths | 3 | 3% | 49 | 28% |
| Pulmonary deaths | 0 | 0% | 15 | 8% |
| . | Placebo + HDAC (N = 86) . | Laromustine + HDAC (N = 177) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Adverse events with death | 11 | 13% | 71 | 40% |
| Infectious deaths | 3 | 3% | 49 | 28% |
| Pulmonary deaths | 0 | 0% | 15 | 8% |
N indicates number of patients; and n, number of deaths.